Clinical Pharmacokinetics of Imatinib
By B. Peng, P. Lloyd, H. Schran. Clinical Pharmacokinetics, 2005
654 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/27e418c2812d6cdecf6c050b4366bf3ea31ac432
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008, background): “Imatinib has favorable pharmacokinetic (PK) characteristics, including rapid and complete oral bioavailability (98%) and a proportional dose-exposure relationship.(7,8) Its terminal half-life is approximately 20 hours, allowing for once daily dosing.”